Relapsed acute lymphoblastic leukaemia (ALL) is associated with resistance to chemotherapy and poor prognosis 1 . Gain-offunction mutations in the 5′-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine and are selectively present in relapsed ALL 2,3 . Yet, the mechanisms involved in NT5C2 mutation-driven clonal evolution during the initiation of leukaemia, disease progression and relapse remain unknown. Here we use a conditional-and-inducible leukaemia model to demonstrate that expression of NT5C2(R367Q), a highly prevalent relapsed-ALL NT5C2 mutation, induces resistance to chemotherapy with 6-mercaptopurine at the cost of impaired leukaemia cell growth and leukaemia-initiating cell activity. The loss-of-fitness phenotype of NT5C2 +/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool. Consequently, blocking guanosine synthesis by inhibition of inosine-5′-monophosphate dehydrogenase (IMPDH) induced increased cytotoxicity against NT5C2-mutant leukaemia lymphoblasts. These results identify the fitness cost of NT5C2 mutation and resistance to chemotherapy as key evolutionary drivers that shape clonal evolution in relapsed ALL and support a role for IMPDH inhibition in the treatment of ALL.
out of the cell 14, 15 . In addition, NT5C2 metabolizes and inactivates the active metabolites that mediate the cytotoxic activity of 6-mercaptopurine (6-MP), a purine analogue chemotherapy drug that is broadly used in the treatment of ALL 16 (Extended Data Fig. 1 ). Expression of gainof-function relapse-associated mutant forms of NT5C2 can therefore induce resistance to 6-MP in vitro 2, 3 .
Genomic profiling of matched samples from the time of ALL diagnosis and after relapse supports the hypothesis that cellular competition and chemotherapy resistance work as dynamic evolutionary forces that shape the clonal architecture of ALL [8] [9] [10] . To test this hypothesis we generated a knock-in mouse model (Nt5c2 +/co-R367Q ) for conditional expression of Nt5c2(R367Q) (Extended Data Fig. 2) , the most common NT5C2 mutation found in relapsed ALL 2, 3 , and gene rated primary NOTCH1-induced Rosa26 +/CreERT2 Nt5c2 +/co-R367Q T-ALL tumours 17, 18 (Extended Data Fig. 2 ) with conditional tamoxifeninducible expression of Nt5c2(R367Q) ( Fig. 1a and Extended Data Fig. 2 ). Treatment of isogenic Nt5c2 wild-type (Nt5c2 +/co-R367Q , vehicle-treated) and Nt5c2 +/R367Q mutant (Nt5c2 +/co-R367Q , 4-hydroxytamoxifen-treated) leukaemia cells with increasing concentrations of 6-MP showed overt resistance to thiopurine chemotherapy specifically in Nt5c2 +/R367Q mutant cells (Fig. 1b) . Moreover, Nt5c2 +/R367Q mutant cells were positively selected in a dose-dependent manner over isogenic wild-type Nt5c2 +/co-R367Q tumour cells under 6-MP treatment in vitro (Fig. 1c ). Treatment of mice harbouring isogenic Nt5c2 +/co-R367Q (vehicle treated, wild-type group) or Nt5c2 +/R367Q (tamoxifen treated, mutant group) leukaemias with 6-MP produced a dose-dependent response in Nt5c2 +/co-R367Q wild-type tumours and overt resistance with progression in Nt5c2 +/R367Q mutant leukaemias (Fig. 1d , e and Extended Data Fig. 2g ). Moreover, 6-MP treatment of mixed tumour populations of isogenic wild-type Nt5c2 +/co-R367Q and mutant Nt5c2 +/R367Q lymphoblasts demonstrated positive selection in vivo of cells harbouring the Nt5c2(R367Q)-encoding mutant allele (Extended Data Fig. 2h ). These results support a direct role for NT5C2(R367Q) as a driver of 6-MP resistance in vivo and are concordant with the strong association of NT5C2 mutations with early relapse and progression during 6-MP maintenance therapy in the clinic 2, 3 .
Recent genomic studies of matched diagnostic and relapsed ALL samples support the hypothesis that relapsed leukaemia emerges from the expansion of pre-existing resistant populations present as minor Letter reSeArCH subclones at the time of diagnosis 19 . To evaluate further the role of NT5C2 as a driver of clonal progression and relapse in ALL, we used ultra-deep sequencing with unique-molecular-identifier barcoding (4,100× coverage) to analyse the presence of NT5C2 mutations in 14 diagnostic DNA samples from cases showing acquired NT5C2 mutations at relapse. Notably, these analyses (1:1,000 sensitivity) failed to detect the corresponding relapse-associated NT5C2 mutant allele at the time of diagnosis (Extended Data Table 1 ). NT5C2(R367Q) allele-specific quantitative PCR (qPCR) (n = 9) (1:1,000 sensitivity) yielded similar negative results (Extended Data Table 1 ). Moreover, in one case bearing the NT5C2(R39Q) mutation at the time of relapse, droplet PCR analysis (1:20,000 sensitivity) detected the presence of this mutation during complete remission 37 days prior to the emergence of clinical relapse (Extended Data Table 1 ). Before then, and at the time of diagnosis, the signal for this mutation (0.00064%) was below the established sensitivity of the assay (0.005%). In a separate case we detected a NT5C2(P414A) mutation in first relapse and a second NT5C2(R39Q) variant in second relapse. In this patient, the NT5C2(P414A) mutation was not detectable by droplet PCR analysis at the time of diagnosis, whereas the mutant allele encoding NT5C2(R39Q) was detected below the 0.005% detection threshold at 0.0024-0.0031% frequency. However, analysis of bone marrow at the time of first relapse detected a NT5C2(R39Q) subclonal population (0.0058%) in addition to the NT5C2(P414A) clone. These NT5C2(R39Q) mutant cells expanded (0.0224%) in a serial sample obtained during a second complete remission 60 days later, while the NT5C2(P414A) mutant clone decreased, becoming clonal at the time of second relapse 50 days later (Extended Data Table 1 ). These results suggest that NT5C2 mutations can be detected in complete-remission samples before relapse, yet, if present in the clonal repertoire at the time of diagnosis, they represent quantitatively minor populations below the sensitivity of molecular assays.
Resistance-driving mutations have been linked to enhanced leukaemia growth and proliferation, clonal expansion at early stages of tumour development and increased leukaemia stem-cell activity [20] [21] [22] . However, studies of resistance to bacterial antibiotics have uncovered frequent examples of evolutionary trade-offs in which the acquisition of drug resistance is coupled with a reduced-fitness phenotype 23 . In this context, we noted that in the absence of chemotherapy, Nt5c2 +/R367Q mouse tumour cells showed decreased proliferation in vitro, a delayed entry into the S phase of the cell cycle ( Fig. 2a, b ) and delayed tumour progression in vivo compared with wild-type Nt5c2 +/co-R367Q isogenic controls ( Fig. 2c ). Moreover, limiting dilution transplantation assays demonstrated a 17-fold reduction of leukaemia-initiating cell activity in mutant Nt5c2 +/R367Q tumour cells ( Fig. 2d -e and Extended Data Table 2 ). Of note, allele expression analysis of tumours recovered from mice transplanted with Nt5c2 +/R367Q leukaemia lymphoblasts showed decreased expression of the mutant Nt5c2 transcripts, suggesting downregulation of the mutant allele encoding Nt5c2(R367Q) during tumour progression in the absence of 6-MP (Extended Data Fig. 3 ). These results support the hypothesis that Nt5c2(R367Q) imposes a notable fitness cost to leukaemia lymphoblasts.
Given the role of NT5C2 in the degradation and export of purine nucleotides 15 , we examined whether imbalances in the intracellular purine-nucleotide pool could mediate the loss-of-fitness phenotype observed in Nt5c2 +/R367Q mutant leukaemia cells. Broad-based metabo lomic analysis showed that NT5C2 activation in Nt5c2 +/R367Q ALL lymphoblasts leads to decreased intracellular levels of NT5C2 substrates (inosine monophosphate, xanthine monophosphate and guanosine monophosphate) and accumulation of downstream nucleo tide products and their metabolites (inosine, hypoxanthine, xanthosine, xanthine, guanine and uric acid) in conditioned media ( Fig. 3 and Supplementary Tables 1, 2) . Similarly, expression of NT5C2(R367Q) of isogenic Nt5c2 +/co-R367Q wild-type and Nt5c2 +/R367Q mutant mouse T-ALL cells. b, Cell cycle progression of Nt5c2 +/co-R367Q and Nt5c2 +/R367Q mouse T-ALL cells. c, Kaplan-Meier survival curve of mice harbouring Nt5c2 +/co-R367Q and Nt5c2 +/R367Q isogenic leukaemias (n = 6 per group). d, Leukaemia-initiating cell analysis in mice bearing Nt5c2 +/co-R367Q or isogenic Nt5c2 +/R367Q leukaemia cells (n = 6 mice per group). e, Confidence intervals (CI) showing 1/(stem-cell frequency) based on d. a, b, Data are from three biological replicates. * P ≤ 0.05, * * P ≤ 0.005, * * * P ≤ 0.001, two-tailed Student's t-test (a, b) or two-sided log-rank test (c).
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in human T-ALL (CUTLL1) and B precursor ALL (REH) cell lines resulted in depletion of intracellular purine nucleotides and increased levels of purine metabolites in the culture media (Extended Data Fig. 4 and Supplementary Tables 3, 4 ). Increased extracellular purine metabolites are consistent with the described activity of NT5C2 in promoting the export of purine nucleotides 15 and might result in potential non-cell autonomous satellite effects modulating nucleotide metabolism and the response to 6-MP in by-standing wild-type NT5C2 cells.
A corollary of these findings is that because of this metabolic imbalance, gain-of-function NT5C2 mutations could be negatively selected during ALL tumour initiation and early disease progression, a time when clonal evolution is driven primarily by competition for microenvironment resources with normal haematopoietic stem and progenitor cells first, and then between different leukaemia clones 24 . Consistent with this model, integrated sequential network (ISN) 25 analysis of mutation dynamics from diagnostic and relapse mutation data identified NT5C2 mutations as late events in the clonal evolution of ALL (Extended Data Fig. 5 ).
We hypothesized that gain-of-function relapse-associated NT5C2 mutations could result in increased leukaemia dependence on purine synthesis, rendering leukaemia lymphoblasts more sensitive to drugs targeting this pathway. Indeed, acquired drug resistance in bacteria can be accompanied by collateral sensitivity to an alternative antibiotic agent 23 . To test this possibility, we analysed the response of Nt5c2 +/co-R367Q wild-type and isogenic Nt5c2 +/R367Q mutant ALL lymphoblasts to mizoribine, an inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH), a rate-limiting enzyme required for the synthesis of guanine nucleotides 26 . Notably, these experiments demonstrated significantly increased sensitivity to mizoribine in Nt5c2 +/R367Q mutant leukaemia cells in vitro compared to Nt5c2 +/co-R367Q wild-type isogenic controls ( Fig. 4a and Extended Data Fig. 6 ). Moreover, guanosine supplementation in the media rescued the effects of mizoribine in 
Nt5c2 +/co-R367Q wild-type and Nt5c2 +/R367Q mutant lymphoblasts, supporting a mechanistic role for nucleotide depletion in the activity of this drug and its synthetic lethal interaction with the mutant allele encoding Nt5c2(R367Q) (Extended Data Fig. 6 ). Similar differential responses to mizoribine in wild-type Nt5c2 +/co-R367Q cells and in Nt5c2 +/R367Q mutant cells were observed in vivo in a subcutaneous lymphoma model (Extended Data Fig. 6 ). Furthermore, treatment of Nt5c2 +/R367Q leukaemia-bearing mice with mizoribine induced a marked in vivo anti-leukaemic response, with significantly improved survival compared with isogenic Nt5c2 +/co-R367Q wild-type controls (P < 0.0001) ( Fig. 4b) . Similarly, expression of gain-of-function NT5C2 mutations (R238W, K359Q, R367Q and D407A) associated with relapse in CUTLL1 and REH ALL cells induced resistance to 6-MP and increased their sensitivity to mizoribine (Extended Data Figs 7, 8) . As before, guanosine supplementation ameliorated the anti-leukaemic effects of mizoribine in this experiment, providing evidence that depletion of nucleotides is the mechanism of action for this drug (Extended Data Figs 7, 8) . Additionally, knockdown of IMPDH2, the gene encoding the main IMPDH isoform expressed in proliferating tissues and tumour cells, led to decreased growth in NT5C2(R367Q)-expressing REH and CUTLL1 cells compared to wild-type NT5C2-expressing lymphoblasts (Extended Data Figs 7, 8) . We also observed resistance to 6-MP with increased sensitivity to mizoribine in leukaemia cells from two human primary xenografts harbouring the mutant NT5C2(R367Q)-encoding allele compared to matched wild-type NT5C2 ALL blasts derived from samples obtained at the time of diagnosis ( Fig. 4c-h ). Moreover, immunodeficient mice transplanted with an NT5C2(R367Q) xenograft derived from a relapsed patient showed decreased tumour burden and tumour infiltration following mizoribine treatment compared to mice transplanted with matched wild-type NT5C2 xenograft cells derived from samples taken at the time of diagnosis (Extended Data Fig. 6 ).
These results document fitness cost and acquired resistance to 6-MP as evolutionary forces that drive the clonal evolution dynamics and selection of relapse-associated NT5C2 mutations in ALL, highlight the relevance of nucleotide export in the control of nucleotide homeostasis 27 and in the context of antimetabolite therapy 28 , and identify collateral sensitivity to IMPDH inhibition as a potentially relevant vulnerability in NT5C2-mutant leukaemia.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. burden of 90% blasts in the bone marrow. To generate conditional Nt5c2(R367Q) knock-in mice we used homologous recombination in C57BL/6 embryonic stem cells to introduce a point mutation (AG→ CA) in exon 14 that caused the R367Q substitution (two nucleotide changes were introduced to replace the mouse R367 codon (AGA) with a glutamine-coding codon (CAA)) as well as a loxP-flanked wild-type mini-gene cassette (1958 bp, inserted 233 bp upstream of exon 14) composed of the fusion of exons 14-18 and flanking genomic sequences upstream of exon 14 and downstream of exon 18. Immediately downstream of the mini-gene we introduced a FRT-flanked neomycin selection cassette. We generated chimaeras in C57BL/6 albino blastocysts using three independent knock-in embryonic stemcell clones identified by PCR analysis and verified by Southern blot. We verified germ-line transmission in the offspring of highly chimaeric male mice crossed with C57BL/6 females. To remove the neomycin selection cassette we crossed mice harbouring the targeting construct with a Flp germ line deleter line (B6;SJL-Tg(ACTFLPe)9205Dym/J, Jackson Laboratory) and crossed the resulting mice with wild-type C57BL/6 to breed out the Flp allele. To generate inducible knock-in mice we bred animals harbouring the Nt5c2 co-R367Q allele with Rosa26 +/creERT2 mice, which express a tamoxifen-inducible form of the Cre recombinase from the ubiquitous Rosa26 locus 31 .
To generate NOTCH1-induced T-ALL tumours in mice, we performed retroviral transduction of bone marrow cells (from Rosa26 +/creERT2 Nt5c2 +/co-R367Q mice) enriched in lineage negative cells isolated using magnetic beads (Lineage Cell Depletion Kit, Miltenyi Biotec) with retroviruses expressing an activated form of the NOTCH1 oncogene (Δ E-NOTCH1) 17 and the green fluorescent protein (GFP) and transplanted them via intravenous injection into lethally irradiated isogenic recipients (6-8-week-old C57BL/6 females, Taconic Farms) as previously described 18, 32 .
We assessed T-ALL tumour development by monitoring CD4 + CD8 + GFP + cells in peripheral blood by flow cytometry. In brief, we incubated blood samples with red blood cell lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 , 0.1 mM EDTA) for 5 min at room temperature three times before staining with APC-Cy7-conjugated antibodies against mouse CD4 (BD Pharmingen-552051) and PE-Cy7-conjugated antibodies against mouse CD8a (eBioscience-25-0081-82). Flow cytometry analyses were performed in a FACSCanto flow cytometer (BD Biosciences) and analysed with Flowjo software (FlowJo LLC).
For all subsequent in vivo studies, we harvested fresh Rosa26 +/creERT2 Nt5c2 +/co-R367Q T-ALL tumour cells from the spleens of donor mice and transplanted them into sublethally irradiated (4 Gy) secondary recipients (C57BL/6 females, 6-8 weeks old, Taconic Farms). Animals were randomly assigned to different treatment groups and no blinding was done. For survival and leukaemia-initiating cell experi ments, we treated mice with tamoxifen (3 mg via intraperitoneal injection) two days after transplantation to induce mini-gene-cassette deletion and expression of the Nt5c2 allele encoding the R367Q mutation in the leukaemic cells, or with corn oil vehicle in the control group (n = 6 mice per group). Mice were then observed for incidence and time of onset of leukaemia.
To detect tamoxifen-inducible mini-gene deletion, we purified DNA from primary Rosa26 +/creERT2 Nt5c2 +/co-R367Q mouse tumour cells treated with 1 μ M 4-hydroxytamoxifen or ethanol vehicle (in vitro experiments) and tamoxifen or corn oil vehicle (in vivo experiments) and then performed PCR-amplification with a three-primer reaction: (i) the minigene cassette (primer immediately upstream of proximal loxP site and reverse primer in exon 17) and (ii) the deleted minigene and wild-type alleles (primer immediately upstream of proximal loxP site and reverse primer in intron 14). The deleted and wild-type alleles differ by the size of the remaining loxP site (49 bp). We visualized PCR products resolved by electrophoresis in a 1.5% agarose gel with ethidium bromide.
To detect tamoxifen-inducible expression of mRNA corresponding to the Nt5c2 allele encoding the R367Q mutation, we purified total RNA from mouse tumour cells with the RNeasy kit (Qiagen), prepared complementary DNA (cDNA) by reverse transcription using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) and PCR amplified the Nt5c2 exon 14 cDNA region using primers spanning neighbouring exons following standard procedures. We analysed the resulting PCR products by dideoxy DNA sequencing to verify the expression of the engineered nucleotide substitutions in the Nt5c2 allele encoding the R367Q mutation.
For experimental therapeutics treatment studies, we used Rosa26 +/creERT2 Nt5c2 +/co-R367Q T-ALL tumour cells infected with lentiviral particles expressing the red cherry fluorescent protein and luciferase (FUW-mCherry-Luc-puro). We transplanted luciferased Rosa26 +/creERT2 Nt5c2 +/co-R367Q T-ALL tumour cells into C57BL/6 recipients by intravenous injection and monitored tumour development by in vivo luminescence bioimaging with the In vivo Imaging System (IVIS, Xenogen) and by flow cytometry using analysis of GFP + cells in peripheral blood. Once mice had 50% GFP positive cells in the peripheral blood and a detectable baseline tumour burden by bioluminescence, we treated them with tamoxifen Letter reSeArCH (3 mg, intraperitoneal injection) or corn oil vehicle as described above. Two days later we initiated treatment with a range of doses of 6-MP (0, 50, 80, 100 mg kg -1 per day) via intraperitoneal injection for five consecutive days (n = 5 mice per group). We monitored disease progression and response to chemotherapy by bioluminescence imaging on days 0, 3 and 6 after the start of 6-MP treatment. We euthanized mice on day 6 and analysed GFP + tumour infiltration in the spleen by flow cytometry. To assess mizoribine response in vivo we treated Rosa26 +/creERT2 Nt5c2 +/co-R367Q leukaemia bearing mice 48 h following tamoxifen or corn oil vehicle treatment (as described above) with 40 mg kg -1 mizoribine or PBS vehicle (n = 10 per group) via intraperitoneal injection for ten consecutive days. Mice were then observed for incidence and time of onset of leukaemia.
For experimental therapeutic treatment studies in a subcutaneous setting, Rosa26 +/creERT2 Nt5c2 +/co-R367Q T-ALL tumour cells infected with lentiviral particles expressing the red cherry fluorescent protein and luciferase (FUW-mCherry-Luc-puro) were treated with 1 μ M 4-hydroxytamoxifen or ethanol vehicle in vitro, mixed with an equal volume of Corning Matrigel Membrane Matrix (Fisher Scientific) and injected (10 6 cells) into the flanks of female C57BL/6 mice. Upon detectable baseline tumour burden by bioluminescence, mice were treated intraperitoneally with PBS vehicle or mizoribine (20, 40, 75 or 100 mg kg -1 per day, n = 4 per dose) for 5 consecutive days. We monitored tumour progression and response to mizoribine by bioluminescence imaging on days 0 and 6 after the start of mizoribine treatment. Subcutaneous tumours were not allowed to exceed 20 mm in diameter.
To evaluate the competitive selection of Nt5c2 +/R367Q cells in vivo we mixed wildtype Nt5c2 +/co-R367Q and Nt5c2 +/R367Q mutant mouse tumour cells at a 1:10, 1:100 and 1:1,000 Nt5c2 +/R367Q :Nt5c2 +/co-R367Q ratios and transplanted into C57BL/6 recipients by intravenous injection. Ten days after transplant, mice were treated with vehicle or 50 mg kg -1 6-MP per day for 5 days, then allowed to recover for ten days and given a second round of treatment for 1-3 days. Following this second cycle of treatment, mice were euthanized and lymphoblasts were recovered from spleen samples for quantitative evaluation of Nt5c2 +/R367Q mutant cells.
We generated primary human leukaemia xenografts by intravenous injection of cryopreserved leukaemia lymphoblasts from diagnostic and relapsed acute lympho blastic leukaemia patient samples into immunodeficient NRG mice.
We infected primary leukaemia xenograft cells with lentiviral particles expressing the red cherry fluorescent protein and luciferase (FUW-mCherry-Lucpuro) and transplanted matched ALL-4 diagnosis and ALL-4 relapse tumour cells into NRG immunodeficient recipients by intravenous injection and monitored tumour development by in vivo luminescence bioimaging with the In vivo Imaging System (IVIS, Xenogen) and by analysis of human CD45 + cells in peripheral blood by flow cytometry with an APC conjugated antibody (eBioscience 17-0459-42). Upon tumour establishment, mice were treated intraperitoneally with PBS vehicle or mizoribine (100 mg kg -1 administered twice a day) for 3 consecutive days. Four animals in the relapse-xenograft mizoribine treatment group did not tolerate the full course of therapy presumably because of tumour lysis syndrome and were not included in the analysis. We euthanized mice on day 4 and analysed spleen weight and CD45 + tumour infiltration in the bone marrow by flow cytometry. In vitro cell viability and chemotherapy response assays. We measured cell growth and chemotherapy responses of primary mouse tumours, patient-derived xenografts, and human ALL cell lines in vitro by measurement of the metabolic reduction of the tetrazolium salt MTT using the Cell Proliferation Kit I (Roche) following the manufacturer's instructions. We analysed chemotherapy responses following 72-h incubation with increasing concentrations of 6-mercaptopurine or mizoribine.
For the mixed culture experiment of isogenic wild-type Nt5c2 +/co-R367Q and Nt5c2 +/R367Q mouse tumour cells, we treated uninfected tumour cells (expressing GFP) with vehicle and treated the same tumour cells previously infected with a mCherry-expressing vector (FUW-mCherry-Luc-puro) with 4-hydroxytamoxifen and quantified proportions of the two cell populations by FACS analysis using a Fortessa flow cytometer (BD Biosciences) and analysed data with FlowJo software (FlowJo LLC). All experiments were performed in triplicate. Cell synchronization and cell cycle analysis. We synchronized isogenic wild-type Nt5c2 +/co-R367Q and Nt5c2 +/R367Q mouse tumour cells using a double thymidine block procedure. In brief, we incubated cells with 2 mM thymidine (Sigma Aldrich) for 16 h, allowed cells to recover for 14 h in regular media, and incubated a second time with 2 mM thymidine for 16 h. We harvested cells at 0, 3, 6 and 9 h time points and stained them with propidium iodide (Sigma Aldrich) for cell cycle progression analysis. FACS analysis was performed using a FACSCanto flow cytometer (BD Biosciences) and we analysed data with FlowJo software (FlowJo LLC). Quantitative allele-specific qPCR assay. We quantitatively assessed the presence of the allele encoding NT5C2(R367Q) in matching DNA specimens obtained at diagnosis and during remission using a custom Mutation Detection Competitive Allele-Specific TaqMan PCR (castPCR) Assay (Life Technologies) using 30 ng of DNA in a reaction volume of 20 μ l in a 7500 real-time PCR system (Applied Biosystems) following the manufacturer's instructions and recommended cycling conditions. We determined a detection Δ C t cut-off value for the assay by running the wild-type and mutant NT5C2 assays on genomic DNA samples from three wild-type cell lines and calibrated both assays by spiking in increasing concentrations of wild-type NT5C2 or of the plasmid containing the NT5C2 allele encoding the R367Q mutation. We determined the assay sensitivity for the allele encoding NT5C2(R367Q) by analysing NT5C2 wild-type genomic DNA samples spiked with decreasing concentrations of the plasmid containing the NT5C2 allele encoding the R367Q mutation. We analysed experimental data using the Mutation Detector Software (Life Technologies) to calculate the Δ C t value between the wild-type NT5C2 and the NT5C2(R367Q)-encoding allele assay reads for each sample, and comparing these to the predetermined Δ C t cut-off value.
To quantitatively assess the presence of Nt5c2 +/R367Q mutant cells in mixed tumour populations of wild-type Nt5c2 +/co-R367Q and Nt5c2 +/R367Q mutant lymphoblasts, we performed a quantitative analyses of mutant transcripts normalizing tumour content by quantitative PCR with reverse transcription (RT-PCR) analysis of GFP. In this experiment we isolated RNA from lymphoblasts with the RNeasy kit (Qiagen) and prepared complementary DNA (cDNA) by reverse transcription using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). Nt5c2 exon 14 was amplified using TaqMan Gene Expression Master Mix (TaqMan) and the allele encoding Nt5c2(R367Q) was detected using a mutant-specific TaqMan probe (5′ FAM-AGGGTGGCAGACTTT-MGBNFQ 3′ , ThermoFisher). Actb (β -actin) and GFP were amplified using FastStart Universal SYBR Green Master (ROX) (Roche) following standard protocols. Quantitative PCR reactions were run in a 7500 Real Time PCR System (Applied Biosystems). C t values of the allele encoding Nt5c2(R367Q) and GFP were normalized to Actb C t values and a ratio was taken of Nt5c2(R367Q) expression over GFP expression to represent the percentage of Nt5c2 +/R367Q mutant cells present in mixed tumour populations. Digital droplet PCR. Targeted ultra-deep mutation screening was performed using the digital droplet PCR technique (RainDance Technologies) as described previously 33 . In brief, TaqMan assay primers and probes were custom designed for the allele encoding NT5C2(P414A) using PrimerExpress 3.0 (Thermo Fisher Scientific). Primers and probes for the allele encoding NT5C2(R39Q) were designed through the Custom TaqMan Assay Design Tool (CADT) (Life Technologies) with the support of RainDance Technologies. Probes matching the wild-type allele were labelled with VIC fluorescent reporter dye and probes matching the mutant allele were labelled with FAM dye. Amplicon sizes ranged from 75 bp to 120 bp. Genomic DNA was sheared to 3 kb using the M220 instrument (Covaris) and a total of 500-1,000 ng of fragmented DNA was used in each 50 μ l ddPCR reaction. The digital droplet PCR reaction further contained 1× TaqMan Genotyping Master Mix (Applied Biosystems), 1× digital PCR droplet stabilizer (RainDance Techonologies), and 1× TaqMan primers and probes mix (Integrated DNA Technologies). In line with the manufacturer's instructions, an average of 7 × 10 6 droplets were generated by the RainDrop Source instrument and emulsion PCR was performed using the C1000 Thermal Cycler (BioRad). Droplet fluorescence of the amplified product was detected by the RainDrop Sense instrument and data analysis was carried out using the RainDrop Analyst II Software (RainDance Techonolgies).
To determine the detection limit of the assays, we constructed dilution curves of patient tumour cells and cells from the REH cell line. The REH cell line was confirmed to be wild type after Sanger sequencing for the locations targeted in the digital droplet PCR. We collected pure populations of tumour cells by flow cytometric sorting of the relapse samples of patients SJBALL192 (containing cells heterozygous for the allele encoding NT5C2(R39Q)). We made serial dilutions of tumour cells with wild-type cells (REH cell line) to generate final mutant allele frequency (MAF) levels of 50%, 5%, 0.5%, 0.05%, 0.005%, and 0.0005% and isolated DNA using phenol-chloroform. With an input of 500 ng DNA in the digital droplet PCR assay the MAFs correspond to 70,000, 7,000, 700, 70, 7, and 0.7 copies, respectively. A frequency of > 0.005% (> 7 copies) could be consistently detected. Duplex sequencing of diagnostic patient samples. Duplex sequencing was carried out by TwinStrand Biosciences under fully blinded conditions using methods previously described 34, 35 . In brief, 400 ng of extracted genomic DNA was ultrasonically sheared, A-tailed and ligated to degenerate tag-containing Duplex adapters. The library was amplified and subjected to two successive rounds of hybrid capture with 120 bp biotinylated oligonucleotide probes tiled across exons 9, 11, 13, 15, 16 and 17 of the human NT5C2 gene and flanking sequences. Indexed libraries were pooled and sequenced on an Illumina NextSeq 500. Duplex consensus sequences were generated after alignment to hg38 using the requirement that error-corrected bases be supported by at least three independent reads from each original strand. The variant calls for each sample were filtered against known single nucleotide polymorphisms in the Phase 3 build of the 1000 genomes database and tabulated versus all reference base calls at the eight codons of interest. Variant allele frequency was calculated as the number of variants per total number of error-corrected bases at each nucleotide position. The average error-corrected molecular depth at codons of interest was approximately 4,100× (1,840-8,530× ), yielding an average power for detecting variants at a level of 1/1,000 of ~ 98%. Metabolomic analyses. To analyse metabolic differences between Nt5c2 +/co-R367Q and Nt5c2 +/R367Q primary mouse tumours, we treated tumour cells in triplicate with 1 μ M 4-hydroxytamoxifen for 48 h in vitro to induce expression of the allele encoding Nt5c2(R367Q) or with vehicle for wild-type controls, after which we diluted out the 4-hydroxytamoxifen or vehicle with media. After 72 h, we harvested cells into packed 50-100-μ l size pellets and collected conditioned media for analyses (n = 3, cell pellets and media). We flash-froze cell pellet and media samples, which were then extracted using standard solvent extraction methods and analysed on the gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry platforms by Metabolon. Analysed metabolites consisted of a total of 459 named biochemicals in cells and 252 named biochemicals in media. We first normalized results to protein concentration, log transformed and imputed any missing values with the minimum observed value for each compound. We then used Welch's two-sample t-test to identify biochemicals that differed significantly between experimental groups. To account for the multiple comparisons that occur in metabolomics studies we also calculated an estimate of the false discovery rate (q-value), which indicates the fraction of biochemicals that would meet a given P-value cut-off by random chance. Similar processing and analyses were performed on CUTLL1 and REH ALL cell lines expressing wild-type NT5C2 or NT5C2(R367Q). Analysed metabolites in these cell lines consisted of a total of 596 named biochemicals in cells and 347 in media. ISN of relapsed ALL. We illustrated the sequential order of somatic mutations in relapsed ALL using the ISN 25 that pools evolutionary paths across all patients. We selected recurrently mutated genes that were previously defined as drivers of paediatric ALL 36-38 and relapse-genes 10, 11 . Only non-synonymous single nucleotide variants were used in analysis. For each patient, we generated a sequential network that defined early events as mutations observed in both the primary tumour and the relapsed tumour, whereas late events were mutations only observed in the relapsed tumour. Each node represented a gene, and each arrow pointed from a gene with an early event to a gene with a late event. The ISN then pooled sequential networks across all patients. To test whether a gene within the ISN was significantly early or late, we used the binomial test based on the in-degree and out-degree of each node. Somatic mutation data used to generate ISN were aggregated from previously published studies (refs 9-11). Statistical analyses. We performed statistical analysis by Student's t-test. We considered results with P < 0.05 as statistically significant. Survival in mouse experiments was represented with Kaplan-Meier curves and significance was estimated with the log-rank test (GraphPad Prism). We analysed serial limited dilution leukaemia-initiating cell data using the ELDA software 39 . No outlier data points were excluded in the analyses. Data availability. All data generated or analysed during this study are included in this published article and its Supplementary Information. 
Extended Data Figure 1 | Schematic representation of 6-MP activation and mechanism of action. The hypoxanthine-guanine phosphoribosyl transferase enzyme (HPRT) processes 6-MP to thio-IMP, which is then converted to thio-XMP and thio-GMP. Subsequent metabolism of thio-GMP by kinases and reductases yields thio-dGTP which is incorporated into replicating DNA strands and triggers the DNA mismatch-repair machinery, leading to cell cycle arrest and apoptosis. The anti-leukaemic effects of 6-MP are in part also attributed to a second metabolic pathway in which thiopurine S-methyl transferase (TPMT) methylates thio-IMP to form methylthio-IMP (MeTIMP), which is a potent inhibitor of amidophosphoribosyltransferase (ATase), an enzyme catalysing the committed step of de novo purine biosynthesis. 

Extended Data Figure 2 | Conditional knock-in targeting of Nt5c2, generation and analysis of a Nt5c2(R367Q) conditional inducible T-ALL model. a, Schematic representation of the targeting strategy for the generation of Nt5c2 +/co-R367Q conditional knock-in mice. b, Southern blot analysis of DNA samples from Nt5c2 +/+ and targeted Nt5c2 +/co-R367Q embryonic stem cells after digestions with BamHI restriction enzyme and hybridization of a DNA probe external to the long arm. c, Southern blot analysis of DNA samples from Nt5c2 +/+ and targeted Nt5c2 +/co-R367Q embryonic stem cells after digestion with ApaI restriction enzyme and hybridization of a DNA probe to the short arm. d, Schematic depiction of the strategy for developing conditional inducible Nt5c2 +/co-R367Q primary mouse T-ALL tumours and for assessing the role of Nt5c2 +/R367Q on leukaemia progression and response to chemotherapy. e, Representative FACS plot of a Rosa26 +/creERT2 Nt5c2 +/co-R367Q Δ E-NOTCH1-induced primary T-ALL tumour with a CD4 + CD8 + immunophenotype. f, Representative genotyping PCR results from genomic DNA of a Rosa26 +/CreERT2 Nt5c2 +/co-R367Q Δ E-NOTCH1-induced primary T-ALL tumour treated with 4-hydroxytamoxifen (TMX) or vehicle only (ethanol, ETOH) in vitro showing Cre-mediated deletion of the exon 14-18 Nt5c2 wild-type mini-gene. g, Tumour burden assessed in the spleen (percentage of GFP + cells) in mice allografted with NOTCH1-induced Nt5c2 +/co-R367Q and isogenic Nt5c2 +/R367Q primary leukaemia cells treated with a range of 6-MP doses (n = 5 per group). h, Analysis of selection for the mutant allele encoding Nt5c2(R367Q) by qPCR in mice allografted with Nt5c2 +/co-R367Q and Nt5c2 +/R367Q primary mouse T-ALL cells at a 1:10, 1:100 and 1:1,000 Nt5c2 +/R367Q :Nt5c2 +/co-R367Q dilution and treated with vehicle or 6-MP (n = 5 mice per group and n = 3 technical replicates for the controls). The horizontal bar represents mean values. P values were calculated using twotailed Student's t-test (g) or a one-tailed Student's t-test (h). Data in e and f show representative results from more than two experiments.
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Extended Data Figure 3 | Decreased expression of the allele encoding Nt5c2(R367Q) allele upon leukaemia progression in vivo.
Sanger sequencing chromatograms of cDNA from tumours in Fig. 2c show decreased expression of the Nt5c2(R367Q)-encoding allele over the wild-type Nt5c2 allele compared with recently 4-hydroxytamoxifen treated Rosa26 +/creERT2 Nt5c2 +/co-R367Q cells (Fig. 1a ). Mutant-allele deoxynucleotides are indicated in red. T-ALL 11  K359Q  T-ALL 22 R238W Corresponding author(s): Adolfo Ferrando
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Data exclusions
Describe any data exclusions. No animals were excluded
Replication
Describe whether the experimental findings were reliably reproduced.
All experiments were performed in three biological replicates and independently reproduced as indicated in figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not used.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding techniques were not used.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
Statistical analyses were performed using GraphPad Prism 7.0. Limited dilution leukemia-initiating cell data was analyzed by ELDA software. Adobe Illustrator was used to assemble the figures.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
No restrictions
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
APC-Cy7 anti-CD4 (BD Pharmingen-552051) and PE-Cy7 anti-CD8a (eBiosciences-25-0081-82) were validated by manufacturers. 
